Thomas Shrader
Stock Analyst at BTIG
(3.36)
# 1,018
Out of 5,124 analysts
72
Total ratings
49.21%
Success rate
4.48%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences | Maintains: Buy | $72 → $147 | $93.21 | +57.71% | 3 | Jan 7, 2026 | |
| IVVD Invivyd | Reiterates: Buy | $10 | $2.38 | +320.17% | 2 | Dec 23, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Buy | $32 | $17.21 | +85.94% | 3 | Dec 5, 2025 | |
| NRXP NRx Pharmaceuticals | Reiterates: Buy | $25 | $2.39 | +946.03% | 1 | Dec 3, 2025 | |
| BHVN Biohaven | Reiterates: Buy | $16 | $9.62 | +66.32% | 5 | Nov 18, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $27 | $15.08 | +79.05% | 1 | Nov 17, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $15 → $16 | $5.25 | +204.76% | 3 | Nov 13, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $85 | $44.85 | +89.52% | 6 | Nov 10, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $9 | $4.06 | +121.67% | 2 | Nov 10, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $39 | $35.22 | +10.73% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.43 | +133.24% | 3 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $23 | $6.61 | +247.96% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.69 | - | 4 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $2.55 | +252.94% | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $14 | $7.05 | +98.58% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $63 | $53.50 | +17.76% | 3 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.56 | - | 3 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.76 | +127.27% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.95 | - | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $7.69 | +2,500.78% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $4.21 | +1,325.18% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $5.10 | +37.25% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.43 | +2,919.74% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.96 | +1,022.45% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.28 | +3,884.38% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $8.49 | +88.46% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.02 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.32 | +127.27% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $182.61 | +89.47% | 3 | Feb 21, 2019 |
Bright Minds Biosciences
Jan 7, 2026
Maintains: Buy
Price Target: $72 → $147
Current: $93.21
Upside: +57.71%
Invivyd
Dec 23, 2025
Reiterates: Buy
Price Target: $10
Current: $2.38
Upside: +320.17%
Denali Therapeutics
Dec 5, 2025
Reiterates: Buy
Price Target: $32
Current: $17.21
Upside: +85.94%
NRx Pharmaceuticals
Dec 3, 2025
Reiterates: Buy
Price Target: $25
Current: $2.39
Upside: +946.03%
Biohaven
Nov 18, 2025
Reiterates: Buy
Price Target: $16
Current: $9.62
Upside: +66.32%
Alto Neuroscience
Nov 17, 2025
Initiates: Buy
Price Target: $27
Current: $15.08
Upside: +79.05%
Coya Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $5.25
Upside: +204.76%
Vaxcyte
Nov 10, 2025
Reiterates: Buy
Price Target: $85
Current: $44.85
Upside: +89.52%
Aldeyra Therapeutics
Nov 10, 2025
Reiterates: Buy
Price Target: $9
Current: $4.06
Upside: +121.67%
Stoke Therapeutics
Nov 5, 2025
Reiterates: Buy
Price Target: $39
Current: $35.22
Upside: +10.73%
Nov 4, 2025
Reiterates: Buy
Price Target: $8
Current: $3.43
Upside: +133.24%
Oct 22, 2025
Maintains: Buy
Price Target: $48 → $23
Current: $6.61
Upside: +247.96%
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.69
Upside: -
Oct 15, 2025
Reiterates: Buy
Price Target: $9
Current: $2.55
Upside: +252.94%
Oct 13, 2025
Maintains: Buy
Price Target: $7 → $14
Current: $7.05
Upside: +98.58%
Sep 29, 2025
Reiterates: Buy
Price Target: $63
Current: $53.50
Upside: +17.76%
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.56
Upside: -
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.76
Upside: +127.27%
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.95
Upside: -
Oct 3, 2023
Initiates: Buy
Price Target: $200
Current: $7.69
Upside: +2,500.78%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $4.21
Upside: +1,325.18%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $5.10
Upside: +37.25%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.43
Upside: +2,919.74%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.96
Upside: +1,022.45%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.28
Upside: +3,884.38%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $8.49
Upside: +88.46%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.02
Upside: -
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.32
Upside: +127.27%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $182.61
Upside: +89.47%